Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer

Mohamed A. Ahmed; Edgar Selzer; Wolfgang Dörr; Gerd Jomrich; Felix Harpain; Gerd R. Silberhumer; Leonhard Müllauer; Klaus Holzmann; Bettina Grasl-Kraupp; Michael Grusch; Walter Berger; Brigitte Marian

doi:10.18632/oncotarget.27186

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer

PDF | How to cite

Oncotarget. 2019; 10:5385-5386. https://doi.org/10.18632/oncotarget.27186

Metrics: PDF 931 views | ?

Mohamed A. Ahmed^1,2, Edgar Selzer³, Wolfgang Dörr^3,4, Gerd Jomrich⁵, Felix Harpain⁵, Gerd R. Silberhumer⁵, Leonhard Müllauer⁶, Klaus Holzmann¹, Bettina Grasl-Kraupp¹, Michael Grusch¹, Walter Berger¹, Brigitte Marian¹

¹ Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Austria
² Radiation Biology Department, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Egypt
³ Department of Radiotherapy and Radiobiology, Medical University of Vienna, Austria
⁴ Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Austria
⁵ Department of Surgery, Medical University Vienna, Austria
⁶ Clinical Institute of Pathology, Medical University Vienna, Austria

Published: September 03, 2019

This article has been corrected: While analyzing the same patient cohort for different markers, the authors realized a mistake in Table 2. The table reports on the correlation of radiation therapy response and FGFR4 immunoreactivity score. For both data sets, the stratification criteria were more stringent than mentioned in the table. However, the numerical results reported in the table were re-checked and found to be correct. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:60885–60895. DOI: https://doi.org/10.18632/oncotarget.12099.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27186

Publication Alerts

Corrections:

Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer